Review of Solubilization Techniques for a Poorly Water-Soluble Drug: Carbamazepine

References

1. 1.↵
   1. Leuner C.,
   2. Dressman J.

   Improving drug solubility for oral delivery using solid dispersions. Eur. J. Pharm. Biopharm. 2000, 50 (1), 47–60.

   OpenUrlCrossRefPubMedWeb of Science
2. 2.↵
   1. Riad L. E.,
   2. Chan K. K.,
   3. Wagner W. E.

   Simultaneous first and zero order absorption of carbamazepine tablets in humans. J. Pharm. Sci. 1986, 75 (9), 897–900.

   OpenUrlPubMed
3. 3.↵
   1. Reynolds James E. F.

   Martindale: The Extra Pharmacopoeia, 28th ed.; Reynolds James E. F. Ed.; The Pharmaceutical Press: London, 1982.
4. 4.↵
   1. Aldenkamp A. P.,
   2. Rentmeester T.,
   3. Hulsman J.,
   4. Majoie M.,
   5. Doelman J.,
   6. Diepman L.,
   7. Schellekens A.,
   8. Franken M.,
   9. Olling M.

   Pharmacokinetics and cognitive effects of carbamazepine formulations with different dissolution rates. Eur. J. Clin. Pharmacol. 1998, 54 (2), 184–192.

   OpenUrl
5. 5.↵
   1. Bell W. L.,
   2. Crawford I. L.,
   3. Shiu G. K.

   Reduced bioavailability of moisture-exposed carbamazepine resulting in status epilepticus. Epilepsia 1993, 34 (6), 1102–1104.

   OpenUrlPubMed
6. 6.↵
   1. Meyer M. C.,
   2. Straughn A. B.,
   3. Jarvi E. J.,
   4. Wood G. C.,
   5. Pelsor F. R.,
   6. Shah V. P.

   The bioinequivalence of carbamazepine tablets with a history of clinical failures. Pharm. Res. 1992, 9 (12), 1612–1616.

   OpenUrlPubMed
7. 7.↵
   1. Wang J. T.,
   2. Shiu G. K.,
   3. Ong-Chen T.,
   4. Vishwanathan C. T.,
   5. Skelly J. P.

   Effects of humidity and temperature on in vitro dissolution of carbamazepine tablets. J. Pharm. Sci. 1993, 82 (10), 1002–1005.

   OpenUrlPubMed
8. 8.↵
   1. Zakkinios P. N.,
   2. Li W. I.,
   3. Drennen J. K.,
   4. Lodder R. A.

   Spectrophotometric prediction of the dissolution rate of Carbamazepine tablets. Pharm. Res. 1991, 8 (8), 974–978.

   OpenUrlPubMed
9. 9.↵
   1. Kala H.,
   2. Haack U.,
   3. Pollandt P.,
   4. Bresesinsky G.

   Zur polymorphie des carbamazepins. Aca Pharm. Technol. 1986, 32, 72–77.

   OpenUrl
10. 10.↵
    1. Lefebvre C.,
    2. Goyot-Hermann A. M.,
    3. Draguet-Brugmans M.,
    4. Bouche R.,
    5. Guyot J. C.

    Polymorphic transitions of carbamazepine during grinding and compression. Drug Dev. Ind. Pharm. 1986, 12 (11–13), 1913–1927.

    OpenUrl
11. 11.↵
    1. Krahn F. U.,
    2. Mielckh J. B.

    Effect of type and extent of crystalline order on chemical and physical stability of carbamazepine. Int. J. Pharm. 1989, 53 (1), 25–34.

    OpenUrl
12. 12.↵
    1. Ceolin R.,
    2. Toscani S.,
    3. Gardette M. F.,
    4. Agafonov V.,
    5. Dzyabchenko A.,
    6. Bachet B.

    X-Ray characterization of the triclinic polymorph of carbamazepine. J. Pharm. Sci. 1996, 86 (9), 1062–1065.

    OpenUrl
13. 13.↵
    1. Otsuka M.,
    2. Ohfusa T.,
    3. Matsuda Y.

    Effect of binders on polymorphic transformation kinetics of carbamazepine in aqueous solution. Colloids surfaces B: Biointerf. 2000, 17 (3), 145–152.

    OpenUrl
14. 14.↵
    1. Katzhendler I.,
    2. Azoury R.,
    3. Friedman M.

    Crystalline properties of carbamazepine in sustained release hydrophilic matrix tablets based on hydroxypropyl methylcellulose. J. Controlled Release 1998, 54 (1), 69–85.

    OpenUrlPubMed
15. 15.↵
    1. Luhtala S.

    Effect of sodium lauryl sulphate and polysorbate 80 on crystal growth and aqueous solubility of carbamazepine. Acta Pharm. Nord. 1992, 4 (2), 85–90.

    OpenUrl
16. 16.↵
    1. Laine E.,
    2. Tuominen V.,
    3. Ilvessalo P.,
    4. Kahela P.

    Formation of dihydrate from carbamazepine anhydrate in aqueous conditions. Int. J. Pharm. 1984, 20 (3), 307–314.

    OpenUrl
17. 17.↵
    1. Young W. W.,
    2. Suryanarayanan R.

    Kinetics of transition of anhydrous carbamazepine to carbamazepine dihydrate in aqueous suspensions. J. Pharm. Sci. 1991, 80 (5), 496–500.

    OpenUrlPubMed
18. 18.↵
    1. Kaneniwa T.,
    2. Ichikawa J.,
    3. Yamaguchi T.,
    4. Watari N.,
    5. Otsuka M.

    Hygroscopicity of carbamazepine crystalline powders. Yakugaku Zasshi 1984, 104 (2), 184–190.

    OpenUrlPubMed
19. 19.↵
    1. Young W. W.,
    2. Suryanarayanan R.

    Kinetics of transformation of anhydrous carbmazepine to carbamazepine dihydrate in aqueous suspensions. J. Pharm. Sci. 1991, 80 (5), 496–500.

    OpenUrlPubMed
20. 20.↵
    1. Otsuka M.,
    2. Hasegawa H.,
    3. Matsuka Y.

    Effect of polymorphic transformation during the extrusion granulation process on the pharmaceutical properties of carbamazepine granules. Chem. Pharm. Bull. 1997, 45 (5), 894–898.

    OpenUrl
21. 21.↵
    1. Sethia S.,
    2. Squillante E.

    Solid dispersions: revival with greater possibilities and applications in oral drug delivery. Crit. Rev. Ther. Drug Carrier Syst. 2003, 20 (2–3), 215–247.

    OpenUrlPubMed
22. 22.↵
    1. Bates T. R.

    Dissolution characteristics of reserpine-polyvinylpyrrolidone co-precipitates. J. Pharm. Pharmacol. 1969, 21 (10), 710–712.

    OpenUrlPubMed
23. 23.↵
    1. Corrigan O. I.,
    2. Crean A. M.

    Comparative physicochemical properties of hydrocortisone-PVP composites prepared using supercritical carbon dioxide by the GAS anti-solvent recrystallization process, by coprecipitation and by spray drying. Int. J. Pharm. 2002, 245 (1–2), 75–82.

    OpenUrlPubMed
24. 24.↵
    1. Sekikawa H.,
    2. Naganuma R.,
    3. Fujiwara J.,
    4. Nakano M.,
    5. Arita T.

    Dissolution behaviour and gastrointestinal absorption of tolbutamide in tolbutamide-polyvinylpyrrolidone coprecipitates. Chem. Pharm. Bull. 1979, 27, 31–37.

    OpenUrlPubMed
25. 25.↵
    1. Simonelli A. P.,
    2. Mehta S. C.,
    3. Higuchi W. I.

    Dissolution rates of high energy polyvinylpyrrolidone (PVP)-sulfathiazole coprecipitates. J. Pharm. Sci. 1969, 58 (5), 538–549.

    OpenUrlPubMed
26. 26.↵
    1. Sethia S.,
    2. Squillante E.

    Solid dispersion of carbamazepine in PVP K 30 by conventional solvent evaporation and supercritical methods. Int. J. Pharm. 2004, 272 (1–2), 1–10.

    OpenUrlPubMed
27. 27.↵
    1. Sethia S.,
    2. Squillante E.

    Physicochemical characterization of solid dispersions of carbamazepine formulated by supercritical carbon dioxide and conventional solvent evaporation method. J. Pharm. Sci. 2002, 91 (9), 1948–1957.

    OpenUrlPubMed
28. 28.↵
    1. Sethia S.,
    2. Squillante E.

    In vitro-in vivo evaluation of supercritical processed solid dispersions: permeability and viability assessment in Caco-2 cells. J. Pharm. Sci. 2004, 93 (12), 2985–2992.

    OpenUrlPubMed
29. 29.↵
    1. Moneghini M.,
    2. Kikic I.,
    3. Voinovich D.,
    4. Perissutti B.,
    5. Filipovic-Grcic J.

    Processing of carbamazepine-PEG 4000 solid dispersions with supercritical carbon dioxide: preparation, characterization, and in vitro dissolution. Int. J. Pharm. 2001, 222 (1), 129–138.

    OpenUrlPubMed
30. 30.↵
    1. Nair R.,
    2. Gonen S.,
    3. Hoag S. W.

    Influence of polyethylene glycol and povidone on the polymorphic transformation and solubility of carbamazepine. Int. J. Pharm. 2002, 240 (1–2), 11–22.

    OpenUrlPubMed
31. 31.↵
    1. Biswas M.,
    2. Akogyeram C. O.,
    3. Scott K. R.,
    4. Potti G. K.,
    5. Gallelli J. F.,
    6. Habib M. J.

    Development of carbamazepine:phospholipids solid dispersion formulations. J. Controlled Release 1993, 23 (3), 239–245.

    OpenUrl
32. 32.↵
    1. El-Zein H.,
    2. Riad L.,
    3. Abd El-Bary A.

    Enhancement of carbamazepine dissolution: in vitro and in vivo evaluation. Int. J. Pharm. 1998, 168 (2), 209–220.

    OpenUrl
33. 33.↵
    1. Moneghini M.,
    2. Voinovich D.,
    3. Perissutti B.,
    4. Princivalle F.

    Action of carriers on carbamazepine dissolution. Pharm. Dev. Technol. 2002, 7 (3), 289–296.

    OpenUrlPubMed
34. 34.↵
    1. Zerrouk N.,
    2. Chemtob C.,
    3. Arnaud P.,
    4. Toscani S.,
    5. Dugue J.

    In vitro and in vivo evaluation of carbamazepine-PEG 6000 solid dispersions. Int. J. Pharm. 2001, 225 (1–2), 49–62.

    OpenUrlPubMed
35. 35.↵
    1. Hirasawa N.,
    2. Okamoto H.,
    3. Danjo K.

    Lactose as a low molecular weight carrier of solid dispersions for carbamazepine and ethenzamide. Chem. Pharm. Bull. 1999, 47 (3), 417–420.

    OpenUrlPubMed
36. 36.↵
    1. Perissutti B.,
    2. Newton J. M.,
    3. Podczeck F.,
    4. Rubessa F.

    Preparation of extruded carbamazepine and PEG 4000 as a potential rapid release dosage form. Eur. J. Pharm. Biopharm. 2002, 53 (1), 125–132.

    OpenUrlPubMed
37. 37.↵
    1. Perissutti B.,
    2. Rubessa F.,
    3. Moneghini M.,
    4. Voinovich D.

    Formulation design of carbamazepine fast release tablets prepared by melt granulation technique. Int. J. Pharm. 2003, 256 (1–2), 53–63.

    OpenUrlPubMed
38. 38.↵
    1. Zingone G.,
    2. Rubessa F.

    Release of carbamazepine from solid dispersions with polyvinylpyrrolidone/vinylacetate copolymer. STP Pharm. Sci. 1994, 4 (2), 122–127.

    OpenUrl
39. 39.↵
    1. Giunchedi P.,
    2. Conte U.,
    3. La Manna A.

    A swellable polymer as carbamazepine dissolution rate enhancer. Boll. Chim. Farm. 1990, 129 (1), 17–20.

    OpenUrlPubMed
40. 40.↵
    1. Koester L. S.,
    2. Mayorga P.,
    3. Bassani V. L.

    Carbamazepine/βCD/HPMC solid dispersions. I. Influence of the spray-drying process and βCD/HPMC on the drug dissolution profile. Drug. Dev. Ind. Pharm. 2003, 29 (2), 139–144.

    OpenUrlPubMed
41. 41.↵
    1. Koester L. S.,
    2. Xavier C. R.,
    3. Valquiria P. M.,
    4. Bassani V. L.

    Influence of b-cyclodextrin complexation on carbamazepine release from hydroxypropyl methylcellulose matrix tablets. Eur. J. Pharm. Biopharm. 2003, 55 (1), 85–91.

    OpenUrlPubMed
42. 42.↵
    1. Koester L.,
    2. Bertuol B.,
    3. Groch K. R.,
    4. Xavier C. R.,
    5. Moellerke R.,
    6. Mayorga P.,
    7. Dalla Costa T.,
    8. Bassani V. L.

    Bioavailability of carbamazepine:b-cyclodextrin complex in beagle drugs from hydroxypropylmethylcellulose matrix tablets. Eur. J. Pharm. Sci. 2004, 22 (2–3), 201–207.

    OpenUrlPubMed
43. 43.↵
    1. Betlach C. J.,
    2. Gonzales M. A.,
    3. Mckiernan B. C.,
    4. Neff-Davis C.,
    5. Bodor N.

    Oral pharmacokinetics of carbamazepine in dogs from commercial tablets and a cyclodextrin complex. J. Pharm. Sci. 1993, 82 (10), 1058–1060.

    OpenUrlPubMed
44. 44.↵
    1. Choudhury S.,
    2. Nelson K. F.

    Improvement of oral bioavailability of carbamazepine by inclusion in 2-hydroxypropyl-b-cyclodextrin. Int. J. Pharm. 1992, 85 (1–3), 175–180.

    OpenUrl
45. 45.↵
    1. Brewster M. E.,
    2. Anderson W. R.,
    3. Meinsma D.,
    4. Moreno D.,
    5. Webb A. I.,
    6. Pablo L.

    Intravenous and oral pharmacokinetics evaluation of 2-hydroxyl-propyl-β-cyclodextrin-based formulation of carbamazepine in the dog: comparison with commercially available tablets and suspensions. J. Pharm. Sci. 1997, 86 (3), 335–339.

    OpenUrlCrossRefPubMed
46. 46.↵
    1. Chang R. K.,
    2. Shojaei A. H.

    Effect of hydroxypropyl beta-cyclodextrin on drug solubility in water-propylene glycol mixtures. Drug. Dev. Ind. Pharm. 2004, 30 (3), 297–302.

    OpenUrlPubMed
47. 47.↵
    1. Sarkari M.,
    2. Brown J.,
    3. Chen X.,
    4. Swinnea S.,
    5. Williams R. O. III,
    6. Johnston K. P.

    Enhanced drug dissolution using evaporative precipitation into aqueous solution. Int. J. Pharm. 2002, 243 (1–2), 17–31.

    OpenUrlCrossRefPubMed
48. 48.↵
    1. Mitchell S. A.,
    2. Reynolds T. D.,
    3. Dasbach T. P.

    A compaction process to enhance dissolution of poorly water-soluble drugs using hydroxypropyl methylcellulose. Int. J. Pharm. 2003, 250 (1), 3–11.

    OpenUrlPubMed
49. 49.↵
    1. Machiste E. O.,
    2. Giunchedi P.,
    3. Setti M.,
    4. Conte U.

    Characterization of carbamazepine in systems containing a dissolution rate enhancer. Int. J. Pharm. 1995, 126 (1–2), 65–72.

    OpenUrl
50. 50.↵
    1. Friedrich H.,
    2. Fussnegger B.,
    3. Kolter K.,
    4. Bodmeier R.

    Dissolution rate improvement of poorly water soluble drug obtained by adsorbing solutions of drugs in hydrophilic solvents onto high surface area carriers. Eur. J. Pharm. Biopharm. 2005, 62 (2), 171–177.

    OpenUrlPubMed
51. 51.↵
    1. Hu J.,
    2. Rogers T. L.,
    3. Brown J.,
    4. Young T.,
    5. Johnston K. P.,
    6. Williams R. O. III

    Improvement of dissolution rates of poorly water soluble APIs using novel spray freezing into liquid technology. Pharm. Res. 2002, 19 (9), 1278–1284.

    OpenUrlPubMed
52. 52.↵
    1. Nokhodchi A.,
    2. Bolourtchian N.,
    3. Dinarvand R.

    Dissolution and mechanical behaviors of recrystallized carbamazepine from alcohol solution in the presence of additives. J. Cryst. Growth 2005, 274 (3–4), 573–584.

    OpenUrl
53. 53.↵
    1. Pavan Kumar M.,
    2. Apte S. S.,
    3. Madhusudan Rao Y.

    Oral Colloidal Drug Delivery. Thesis submitted to Kakatiya University, India, 2008.